Treatment options for co-morbid chronic lymphocytic leukemia (CLL) patients

Treatment options for co-morbid chronic lymphocytic leukemia (CLL) patients

VJHemOnc

4 years
408 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Barbara Eichhorst, MD from University of Cologne, Cologne, Germany discussing treatment options for co-morbid chronic lymphocytic leukemia (CLL) patients. These individuals face frequent medical problems which have to be taken into consideration when choosing a treatment regimen. Dosage reduced treatment should be considered as an option, for example fludareabine plus cyclophosphamide plus rituximab. Another combination that has shown promising responses is bendamustine plus rituximab. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
Up Next Autoplay